Clinical trial
Pathophysiology of Orthostatic Intolerance
Name
8398
Description
The purpose of this study is to describe the mechanism of orthostatic intolerance, relying on cardiovascular physiological studies. The syndrome is of undetermined etiology, but the syndrome causes impairment of a number of young adults, females more than males, with symptoms of tachycardia, fatigue, lightheadedness, palpitations, blurred vision, chest discomfort, difficulty concentrating, and dizziness with the upright posture. It is believed that many different pathophysiological processes can give rise to this disorder.
Trial arms
Trial start
1996-12-01
Estimated PCD
2025-12-01
Trial end
2025-12-01
Status
Recruiting
Treatment
DAXOR
131-I-Human Serum Albumin Blood Volume Assessment Kit
Arms:
Healthy Control Subjects, Patients
Other names:
Volumex
QSweat
Quantitative Sweat Testing
Arms:
Healthy Control Subjects, Patients
Other names:
QSART, Quantitative Axonal Sudomotor Reflex Testing
Intrinsic Heart Rate
Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Arms:
Healthy Control Subjects, Patients
Other names:
Inderal, IHR
Size
100
Primary endpoint
Physiological abnormalities in orthostatic intolerance
1 day
Eligibility criteria
Inclusion Criteria:
* Orthostatic intolerance
Exclusion Criteria:
* Inability or unwillingness to give informed consent
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-09-21
1 organization
1 product
2 indications
Organization
Satish R. RajProduct
Intrinsic Heart RateIndication
Tachycardia